AUTHORS
Li Li, MD, PhD, Jiangxing LV2, Muharrem Muftuoglu, MD3, Mahesh Basyal, BSc4, Ran Zhao, MSc5, Michael Andreeff, MD, PhD6
AFFILIATIONS
1 UT MD Anderson Cancer Center, Houston, Texas, United States
2 UT MD Anderson Cancer Center, Houston, Texas, United States
3 UT MD Anderson Cancer Center, Houston, Texas, United States
4 UT MD Anderson Cancer Center, Houston, Texas, United States
5 UT MD Anderson Cancer Center, Houston, Texas, United States
6 UT MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Background:
TP53-mutant chronic lymphocytic leukemia (CLL) is associated with a profoundly immunosuppressive tumor microenvironment. CD39 hydrolyzes extracellular ATP and ADP to AMP, whereas CD73 converts AMP to adenosine, which suppresses T-cell activation and effector function. Because CD39 and CD73 can be expressed by different neighboring cell populations, a compartmentalized, trans-cellular adenosine-producing pathway may contribute to immune dysfunction. We investigated the cellular distribution of the CD39/CD73 axis in TP53-mutant CLL and tested whether targeting CD39 could improve the state of CLL-exposed T cells.
Methods:
We reanalyzed a publicly available longitudinal single-cell RNA-sequencing dataset comprising 27 samples from nice patients with CLL (Penter et al., Cancer Discovery, 2021). CLL B cells and conventional CD4 and CD8 T cells were identified, and expression of ENTPD1/CD39 and NT5E/CD73 was compared according to TP53 status at the sample or patient level. The relationships among CD39-positive and CD73-positive CLL-cell fractions and exhausted T-cell abundance were evaluated using Spearman correlation.
To test the functional contribution of CD39, CAR-engineered T cells were used as a standardized antigen-stimulated T-cell model. T cells were cultured alone, cocultured with TP53-mutant MEC1 CLL cells, or cocultured with MEC1 cells in the presence of CD39 blockade. CD4 and CD8 T-cell states were characterized by high-dimensional mass cytometry. Composite exhaustion scores and protein programs related to activation, checkpoints, memory, signaling, metabolism, apoptosis, and proliferation were evaluated.
Results:
CLL B cells from patients with TP53-alteration showed higher CD73 expression than those from TP53-wild-type patients, whereas CD39 expression was comparable between the two groups. In contrast, CD8 T cells from TP53-mutant cases exhibited higher CD39 expression, while no clear TP53-associated differences in CD39 or CD73 expression were observed in CD4 T cells. Together, these compartment-specific expression patterns suggest a trans-cellular adenosine pathway in which CD39 expressed by CD8 T cells may generate AMP that is subsequently converted to immunosuppressive adenosine by CD73 expressed on neighboring CLL cells. Among eight evaluable patients, high-dysfunction T cells comprised 12.0% of the T-cell compartment in TP53-altered CLL (n=3 patients) compared with 4.7% in TP53-wild-type CLL (n=5 patients).
To evaluate T-cell antitumor function against TP53-mutant CLL in vitro, we generated CD19 CAR T cells and cocultured them with MEC1, a TP53-mutant CLL cell line. High-dimensional mass-cytometry analysis demonstrated that MEC1 exposure induced an exhaustion phenotype in CD4 and CD8 CAR T cells, characterized by increased expression of PD-1, TIM-3, TIGIT, LAG-3, CTLA-4, and TOX. Notably, CD39 was upregulated in CD8 CAR T cells following MEC1 coculture, consistent with the increased CD39 expression observed in patient samples.
Functional analysis demonstrated that CD39 blockade improved CAR T-cell control of MEC1 cells across two sequential tumor rechallenges. At approximately 90 hours, CAR T cells alone maintained about 50% killing of MEC1 cells, whereas the addition of CD39 blockade sustained more than 70% killing. These findings indicate that CD39 functionally contributes to T-cell suppression and that targeting CD39 enhances antileukemic T-cell activity in TP53-mutant CLL
These findings support a compartmentalized CD39/CD73 adenosine pathway in TP53-mutant CLL, in which CD39 on CD8 T cells may generate extracellular AMP that is subsequently converted to immunosuppressive adenosine by CD73 on neighboring CLL cells. CD39 blockade reduced CLL-induced T-cell exhaustion, partially restored the T-cell phenotype, and sustained antileukemic activity during repeated tumor challenge. Together, these results identify CD39 as a functional mediator of T-cell suppression and support its further evaluation as a therapeutic target to enhance T-cell immunity in TP53-mutant CLL. Direct measurement of extracellular AMP and adenosine will be required to confirm the proposed trans-cellular pathway.
DISCLOSURES
Li Li, MD, PhD: No relevant conflicts of interest to declare.